Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Daily News

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

Todd Neale

December 12, 2023

News Daily News

Mortality Risk Varies Among Patients With Very High LDL Levels

Michael O'Riordan

November 17, 2023

News Conference News AHA 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

Todd Neale

November 11, 2023

News Daily News

FDA Grants Tirzepatide a New Indication for Obesity Management

L.A. McKeown

November 08, 2023

News Daily News

Lorundrostat, an Aldosterone Synthase Inhibitor, Passes Phase II Hurdle

Todd Neale

September 12, 2023

News Conference News ESC 2023

STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function

Shelley Wood

August 25, 2023

News Daily News

Study Finds No Increased Risk of CVD Years After Infertility Therapies

L.A. McKeown

August 11, 2023

News Conference News ADA 2023

Dramatic Weight Loss, Cardiometabolic Improvement With Retatrutide

L.A. McKeown

June 28, 2023

News Conference News SCAI 2023

DIPRA Quells Fears Over Distal Radial Cath and Hand Function at 1 Year

L.A. McKeown

May 19, 2023

News Features

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

L.A. McKeown

May 12, 2023

News Daily News

Ezetimibe Plus Moderate-Dose Statins May Aid Compliance in the Elderly

Yael L. Maxwell

April 03, 2023

News Daily News

Regaining Weight Won’t Erode CV Risk Factor Benefits Short Term

L.A. McKeown

March 31, 2023

News Daily News

Study Debunks Obesity Paradox in HF, Encourages BMI Alternatives

L.A. McKeown

March 24, 2023

News Daily News

CV Health Profiles Concerning in Bisexual Females, US Data Suggest

L.A. McKeown

February 24, 2023

News Daily News

Obesity and CVD: New Review Highlights Where Tools and Meds Fall Short

Shelley Wood

January 31, 2023

Advertisement

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

Mortality Risk Varies Among Patients With Very High LDL Levels

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

FDA Grants Tirzepatide a New Indication for Obesity Management

Lorundrostat, an Aldosterone Synthase Inhibitor, Passes Phase II Hurdle

STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function

Study Finds No Increased Risk of CVD Years After Infertility Therapies

Dramatic Weight Loss, Cardiometabolic Improvement With Retatrutide

DIPRA Quells Fears Over Distal Radial Cath and Hand Function at 1 Year

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

Ezetimibe Plus Moderate-Dose Statins May Aid Compliance in the Elderly

Regaining Weight Won’t Erode CV Risk Factor Benefits Short Term

Study Debunks Obesity Paradox in HF, Encourages BMI Alternatives

CV Health Profiles Concerning in Bisexual Females, US Data Suggest

Obesity and CVD: New Review Highlights Where Tools and Meds Fall Short

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content